• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dabigatran, intracranial hemorrhage, and the neurosurgeon.
Abstract Dabigatran etexilate (Pradaxa) is a novel oral anticoagulant that has gained FDA approval for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In randomized trials, the incidence of hemorrhagic events has been demonstrated to be lower in patients treated with dabigatran compared with the traditional anticoagulant warfarin. However, dabigatran does not have reliable laboratory tests to measure levels of anticoagulation and there is no pharmacological antidote. These drawbacks are challenging in the setting of intracerebral hemorrhage. In this article...
Source: Neurosurgical Focus - May 1, 2013 Category: Neurosurgery Authors: Awad AJ, Walcott BP, Stapleton CJ, Yanamadala V, Nahed BV, Coumans JV Tags: Neurosurg Focus Source Type: research